Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind (Test Products and Placebo), Chronic Dosing (24 Weeks), Placebo-Controlled, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo
Brief Summary: This is a multicenter, randomized, double-blind, parallel group, chronic-dosing (24 weeks), placebo-controlled study to assess the efficacy and safety of Glycopyrrolate (GP and Formoterol Fumarate (FF) combination metered-dose inhaler (MDI) (GFF; PT003), GP MDI (PT001), and FF MDI (PT005) compared with Placebo MDI in subjects with moderate to very severe COPD.


Options:
A: Arm Label: MF/F MDI 400/10 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate/formoterol (MF/F) combination | Arm Label: MF/F MDI 200/10 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate/formoterol (MF/F) combination | Arm Label: MF MDI 400 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate MDI (MF MDI) | Arm Label: Formoterol MDI 10 mcg BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol MDI | Arm Label: Placebo MDI BID; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Mometasone furoate/formoterol (MF/F) combination; Assigned to Arm(s): MF/F MDI 400/10 mcg BID | Intervention Type: DRUG; Name: Mometasone furoate/formoterol (MF/F) combination; Assigned to Arm(s): MF/F MDI 200/10 mcg BID | Intervention Type: DRUG; Name: Mometasone furoate MDI (MF MDI); Assigned to Arm(s): MF MDI 400 mcg BID | Intervention Type: DRUG; Name: Formoterol MDI; Assigned to Arm(s): Formoterol MDI 10 mcg BID | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo MDI BID
B: Arm Label: Umeclidinium 62.5 mcg + placebo; Type: EXPERIMENTAL; Interventions: Drug: Umeclidinium, Drug: Umeclidinium matching placebo | Arm Label: Tiotropium 18mcg + placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium, Drug: Tiotropium matching placebo | Intervention Type: DRUG; Name: Umeclidinium; Assigned to Arm(s): Umeclidinium 62.5 mcg + placebo | Intervention Type: DRUG; Name: Umeclidinium matching placebo; Assigned to Arm(s): Umeclidinium 62.5 mcg + placebo | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Tiotropium 18mcg + placebo | Intervention Type: DRUG; Name: Tiotropium matching placebo; Assigned to Arm(s): Tiotropium 18mcg + placebo
C: Arm Label: Tiotropium + Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium bromide, Drug: Placebo Salmeterol | Arm Label: Salmeterol + Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol, Drug: Placebo Tiotropium | Intervention Type: DRUG; Name: Tiotropium bromide; Assigned to Arm(s): Tiotropium + Placebo | Intervention Type: DRUG; Name: Salmeterol; Assigned to Arm(s): Salmeterol + Placebo | Intervention Type: DRUG; Name: Placebo Salmeterol; Assigned to Arm(s): Tiotropium + Placebo | Intervention Type: DRUG; Name: Placebo Tiotropium; Assigned to Arm(s): Salmeterol + Placebo
D: Arm Label: FF MDI (PT005); Type: EXPERIMENTAL; Interventions: Drug: FF MDI (PT005) | Arm Label: GP MDI (PT001); Type: EXPERIMENTAL; Interventions: Drug: GP MDI (PT001) | Arm Label: GFF MDI (PT003); Type: EXPERIMENTAL; Interventions: Drug: GFF MDI (PT003) | Arm Label: Placebo MDI; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: GFF MDI (PT003); Assigned to Arm(s): GFF MDI (PT003) | Intervention Type: DRUG; Name: GP MDI (PT001); Assigned to Arm(s): GP MDI (PT001) | Intervention Type: DRUG; Name: FF MDI (PT005); Assigned to Arm(s): FF MDI (PT005) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo MDI

Answer: D